BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sprycel dasatinib regulatory update

Bristol-Myers submitted an sNDA to FDA for Sprycel dasatinib for first-line treatment of newly diagnosed adult patients with chronic myelogenous leukemia in chronic phase (CML-...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >